Citadel Advisors’s Cocrystal Pharma COCP Stock Holding History

Citadel Advisors’s Portfolio COCP Stock Details COCP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.4K	Buy	+45,118	New	+$55.5K	﹤0.01%	13140
2025 Q2	–	Sell	-10,034	Closed	-$14.2K	–	12844
2025 Q1	$14.2K	Buy	+10,034	New	+$18.7K	﹤0.01%	13373
2022 Q4	–	Sell	-6,660	Closed	-$23K	–	14922
2022 Q3	$23K	Buy	+6,660	New	+$31.2K	﹤0.01%	12018
2021 Q4	–	Sell	-9,028	Closed	-$114K	–	13879
2021 Q3	$114K	Sell	9,028 -117	-1%	-$1.55K	﹤0.01%	12702
2021 Q2	$137K	Buy	+9,145	New	+$139K	﹤0.01%	12593
2020 Q2	–	Sell	-2,406	Closed	-$21K	–	9849
2020 Q1	$21K	Sell	2,406 -544	-18%	-$5.12K	﹤0.01%	9284
2019 Q4	$18K	Buy	+2,950	New	+$29.5K	﹤0.01%	8951
2019 Q3	–	Sell	-1,264	Closed	-$36K	–	9218
2019 Q2	$36K	Buy	1,264 +30	+2%	+$891	﹤0.01%	8824
2019 Q1	$40K	Buy	+1,234	New	+$45.2K	﹤0.01%	8902

Other funds holding COCP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors's COCP Position: Q2 2026 in Review

Citadel Advisors opened a new position in Cocrystal Pharma (COCP) in Q2 2026: 45,118 shares worth $47.4K. The stake represents ﹤0.01% of the portfolio and ranks #13140 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in COCP as recently as Q1 2025.

Citadel Advisors first reported a position in COCP in Q1 2019 and has held it in 9 quarters since. The position peaked at $137K in Q2 2021. 27 funds tracked by Wall St. Rank hold COCP as of Q2 2026.

Citadel Advisors held 45,118 shares of Cocrystal Pharma worth $47.4K as of Q2 2026.
Cocrystal Pharma was a new Citadel Advisors position in Q2 2026.
Cocrystal Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13140 holding.
Citadel Advisors first reported a position in Cocrystal Pharma in Q1 2019 and has held it in 9 quarters since.
Citadel Advisors's Cocrystal Pharma position peaked at $137K in Q2 2021.
27 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.